Supreme Court ruling on genes could help biotech

A Supreme Court decision Thursday barring patents on human genes will likely do little - if any - harm to biotech companies that research and market tests for genetic abnormalities. That's because the other part of the long-anticipated Supreme Court decision upholds patents on so-called cDNA, or complementary DNA: a synthetically produced form of genetic material that can also be tested for abnorm...